Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation.
Journal
Biomedical journal
Journal Volume
47
Journal Issue
3
Start Page
論文號碼 100696
ISSN
2320-2890
Date Issued
2024-06
Author(s)
Su, Yung-Yeh
Chiang, Nai-Jung
Chiu, Tai-Jan
Huang, Chien-Jui
Hsu, Shao-Jung
Lin, Hsin-Chen
Yang, Youngsen
Chou, Wen-Chi
Bai, Li-Yuan
Li, Chung-Pin
Chen, Jen-Shi
Abstract
Pancreatic cancer is a highly aggressive malignancy with a poor prognosis. Over the past decade, significant therapeutic advancements have improved the survival rates of patients with pancreatic cancer. One of the primary factors contributing to these positive outcomes is the evolution of chemotherapy, from monotherapy to doublet or triplet regimens, and the integration of multimodal approaches. Additionally, targeted agents tailored to patients with specific genetic alterations and the development of cell therapies show promise in benefiting certain subpopulations. This article focuses on examining pivotal studies that explore the role of chemotherapy in neoadjuvant, adjuvant, maintenance, and salvage settings; highlights interesting findings related to cell therapy; and provides an overview of ongoing trials concerning metastatic settings. This review primarily aimed to offer recommendations based on therapeutic evidence, recent advancements in new treatment combinations, and the most innovative approaches. A unique aspect of this review is the inclusion of published papers on clinical trials and real-world data in Taiwan, thus adding a valuable perspective to the overall analysis.
Subjects
Chemotherapy
Neoadjuvant therapy
Pancreatic cancer
Postoperative adjuvant chemotherapy
SDGs
Type
journal article